For ALK+ patients rendered NED from oligometastatic NSCLC after resection of both lung primary and isolated CNS lesion, do you consider offering treatment with an ALK inhibitor after adjuvant chemotherapy, or do you place into surveillance?

A large proportion of patients with oligometastatic disease managed with curative intent generally relapse, either intracranially and/or extracranially. TKI therapy maybe expected to prolong disease-free/progression-free survival based on our experience with EGFR TKIs.

However, given the expected du...

A large proportion of patients with oligometastatic disease managed with curative intent generally relapse, either intracranially and/or extracranially. In an analysis of NCDB outcomes, our group showed that NSCLC patients with synchronous brain metastases who underwent thoracic surgery and received...